Accuray reported a strong start to fiscal year 2022, with record first quarter revenue of $107.4 million, driven by investments in product innovation and commercial execution. However, the company experienced a net loss of $1.0 million compared to a net income of $0.4 million in the prior year.
Record net revenue of $107.4 million, including $25.5 million of system revenue in China.
Gross orders increased by 39 percent to $70.0 million compared to the prior year.
GAAP Net loss was $1.0 million, compared to a GAAP Net income of $0.4 million in the prior year.
Received 510(k) clearance for VOLO™ Ultra enhancement to the Accuray Precision® treatment planning system for the Radixact® System.
Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation (“adjusted EBITDA”).
Visualization of income flow from segment revenue to net income